Read the full stored bill text
SB 465-FN - AS AMENDED BY THE SENATE
03/05/2026 0842s
2026 SESSION
26-2002
09/05
SENATE BILL
465-FN
AN ACT
classifying xylazine as a schedule III controlled drug.
SPONSORS: Sen. Gannon, Dist 23; Sen. Abbas, Dist 22; Sen. Birdsell, Dist 19; Sen. Carson, Dist 14; Sen. Rochefort, Dist 1; Sen. McConkey, Dist 3; Rep. L. Walsh, Rock. 15; Rep. Vose, Rock. 5; Rep. Roy, Rock. 31; Rep. Rhodes, Ches. 17
COMMITTEE: Judiciary
─────────────────────────────────────────────────────────────────
ANALYSIS
This bill classifies xylazine as a schedule III controlled drug.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in
bold italics.
Matter removed from current law appears [
in brackets and struckthrough.
]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
03/05/2026 0842s 26-2002
09/05
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty-Six
AN ACT
classifying xylazine as a schedule III controlled drug.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c the following new section:
318-B:1-d Xylazine.
I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of health and human services, xylazine shall be scheduled as a schedule III controlled drug.
II. Notwithstanding paragraph I, nothing in this section shall prevent any licensed veterinarian, as defined in RSA 332-B:1, from doing any of the following:
(a) Dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b.
(b) Dispensing or prescribing for, or administering to, a nonhuman species that is permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b(a)(4).
(c) Another use that is approved or permissible under the Federal Food, Drug, and Cosmetic Act.
2 Effective Date. This act shall take effect January 1, 2027.
LBA
26-2002
04/06/2026
SB 465-FN- FISCAL NOTE
AS AMENDED BY THE SENATE (AMENDMENT #2026-0842s)
AN ACT
classifying xylazine as a schedule III controlled drug.
FISCAL IMPACT:
Estimated State Impact
FY 2026
FY 2027
FY 2028
FY 2029
Revenue
$0
$0
$0
$0
Revenue Fund
None
Expenditures*
Indeterminable
Funding Source
General Fund
Appropriations*
$0
$0
$0
$0
Funding Source
None
*Expenditure = Cost of bill *Appropriation = Authorized funding to cover cost of bill
Estimated Political Subdivision Impact
FY 2026
FY 2027
FY 2028
FY 2029
County Revenue
$0
$0
$0
$0
County Expenditures
Indeterminable
Local Revenue
$0
$0
$0
$0
Local Expenditures
Indeterminable
METHODOLOGY:
This bill adds, deletes, or modifies a criminal penalty, or changes statute to which there is a penalty for violation. Therefore, this bill may have an impact on the judicial and correctional systems, which could affect prosecution, incarceration, probation, and parole costs, for the state, as well as county and local governments. A summary of such costs can be found at:
https://gencourt.state.nh.us/lba/Budget/Fiscal_Notes/JudicialCorrectionalCosts.pdf
AGENCIES CONTACTED:
Judicial Branch, Judicial Council, Department of Justice, Department of Corrections, New Hampshire Association of Counties, and New Hampshire Municipal Association